Cells vs. Parkinson Disease
Seville – Genetrix S.L. and the Botín Foundation will channel a 6m over the next three years into the new company Axontherapix SL. The public-private partnership will seek to develop an effective therapy for Parkinson’s Disease. The prospective therapy is to be based on research performed by López Barneo Virgen, who successfully treated animals with highly dopaminergic stem cells purified from the carotid artery that express GDNF. With the move, Genetrix says it is strengthening its commitment in the stem cell sector, where it already runs two companies, Cellerix and Coretherapix.